Chemical formula: C₁₁H₁₇NO Molecular mass: 179.259 g/mol PubChem compound: 4178
Mexiletine blocks sodium channels with a stronger potency in situations of excessive burst of action potentials (use-dependent block) and/or prolonged depolarization (voltage-dependent block), as occurring in diseased tissues, rather than on physiological excitability (resting or tonic block). Mexiletine is, therefore, mostly active on muscle fibres subject to repeated discharges (such as skeletal muscles). It improves myotonic symptoms by decreasing muscle stiffness through reduction of the delay of muscle relaxation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C01BB02 | Mexiletine | C Cardiovascular system → C01 Cardiac therapy → C01B Antiarrhythmics, class I and III → C01BB Antiarrhythmics, class Ib |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| NAMUSCLA Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Mexiletine is an active ingredient of these brands:
Austria (AT)
Croatia (HR)
Estonia (EE)
France (FR)
Ireland (IE)
Italy (IT)
Japan (JP)Lithuania (LT)
Malta (MT)
Poland (PL)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
